经尿道膀胱黏膜电切术联合塞来昔布治疗肠型腺性膀胱炎的临床效果

Clinical effect of transurethral resection of bladder mucosa combined with celecoxib in the treatment of intestinal cystitis glandularis

目的探讨经尿道膀胱黏膜电切术联合塞来昔布治疗肠型腺性膀胱炎(CG)的有效性和安全性。方法选取2019年1月至2021年6月53例肠型CG患者作为研究对象,按照治疗方式的不同将其分为试验组(n=27,经尿道膀胱黏膜电切术联合塞来昔布治疗)和对照组(n=26,经尿道膀胱黏膜电切术治疗)。比较两组的临床症状评分、术后复发情况及临床疗效。结果术后1、3、6、9、12个月,试验组的临床症状评分均低于术前(P<0.05);术后1、3、6、9、12个月,试验组的临床症状评分低于对照组(P<0.05)。试验组的术后复发率明显低于对照组(P<0.05)。两组的手术均成功完成,无膀胱穿孔、围手术期大出血、输尿管狭窄等并发症发生。试验组的治疗总有效率明显高于对照组(P<0.05)。结论经尿道膀胱黏膜电切术联合塞来昔布治疗肠型CG具有良好的临床效果,可降低疾病复发率。

Objective To investigate the efficacy and safety of transurethral resection of bladder mucosa combined with celecoxib in the treatment of intestinal cystitis glandularis(CG).Methods A total of 53 patients with intestinal CG from January 2019 to June 2021 were selected as the research objects and divided into experimental group(n=27,treated with transurethral resection of bladder mucosa combined with celecoxib)and control group(n=26,treated with transurethral resection of bladder mucosa)according to different treatment methods.The clinical symptom scores,postoperative recurrence and clinical efficacy were compared between the two groups.Results At 13,6,9 and 12 months after operation,the clinical symptom score of the experimental group was lower than that before operation(P<0.05);at 1,3,6,9 and 12 months after operation,the clinical symptom score of the experimental group was lower than that of the control group(P<0.05).The postoperative recurrence rate of the experimental group was significantly lower than that of the control group(P<0.05).The operation of the two groups was successfully completed,and no complications such as bladder perforation,perioperative hemorrhage and ureteral stricture occurred.The total effective rate of treatment in the experimental group was significantly higher than that in the control group(P<0.05).Conclusion Transurethral resection of bladder mucosa combined with celecoxib has a good clinical effect in the treatment of intestinal CG,which can reduce the recurrence rate of the disease.